I saw Bill Miller at the GIBI conference in Dallas and he did indeed pound the table for XON. Richard Perry, who spoke a couple of slots after Bill Miller, also offered parenthetically that he owned it and liked it. I took a flyer based on those 2 very smart guys...who are admittedly as capable as anyone else of being wrong.
This stock is an excellent investment for the long term. Give it another year or two, and PPS will be significantly higher.
Sentiment: Strong Buy
Watching closely, they buy w bid support and selectively buy the heck out of this, then they let it drift (powered in small lots by retail and/or short, imo) and then they come back on weakness and buy 50,000 to 200,000 over 15 min to 30 min...interesting to watch...I think the longs are happy about the lack of interest and coverage. I think this is gonna pop on short covering, it's at the tipping point, lows are behind us, long and strong.
I predict solid earnings out of IXYS - earnings expected on 10/27 - cheap here, perhaps worth a look...got pumped to 14.50 prematurely then flushed out short-term holders with prediction (silly at the time) of $22+, but should be a teenager again soon (in a quarter or 3), jmho
Volume is drying up a bit, and we are at 25 days to cover, as (if) this continues to tick higher (which I believe it will) we can and should be in the 20's fairly soon...I think shorties missed the window with a 16 handle...Kirk has some huge wins under his belt and believes this model is the best thing he has seen...I think he's got the reins on public relations and would prefer to SHOW results more than expose prospects (which seem multi-industry) SOOO many biotechs can partner with Intrexon to mitigate development and production expenses with scalability and giving up FAIR royalty streams...I believe lows are in and we trade 22-28 soon as shorties cover and results are shown (Trans Ova Genetics was a great buy: 2014 likely revenue $70MM+ and $5MM+ in earnings) More good to come from this, keep January high of $38.50 in mind as you acquire on the cheap.
Sentiment: Strong Buy
I owe both ZIOP and XON and it really is hard to tell which is uglier! In both cases the shorts are betting that dilution occurs prior to any meaningful commercial progress. The energy piece of XON intrigues me as I think they may be able to (one day) shift the economics of the space. ZIOP is a harder bet to justify given the virtual news blackout over 2014. Die hard longs are betting near term deal and shorts are betting on yet another dilutive down round.
No news by EOY likely means both drift lower on tax-loss selling. Any upside surprise in either issue would likely have an over-sized effect given the significant short interest in both issues. Kirk has a history of being tight-lipped so let's see if he has any more rabbits in his billionaire#$%$.
XON continues to be technically very weak. The one strong day we saw in the market sell-off has proven to be an anomaly and another opportunity for the shorts to add to positions. Massive short interest is in full control as they view any justification of market cap to be dependent on earnings that could be years away. Despite an extremely impressive of portfolio assets and a limitless future pipeline, the Shorts are willing to press. The chart on XON is UGLY...draw a line diagonally right from the top of the post-IPO high and XON is going to re-test recent lows barring any material news or significant additional insider / institutional buying.
Today's action is quite Bearish.
Completely agree. Histogenics is looking to IPO, so we will get a sense of the "stature" of that partner and perhaps a proxy of how investors view the value of XON as a partner.
I mam prepared to hunker down through a tough EOY. Tax loss selling likely hits many of Kirk's interests and the shorts will press their advantage with the additional (shares) supply. The only way to break the shorts' siege is significant news involving a known partner and good front-end economics.
No follow-through yet today....chart still diagonally negative going back to post IPO high. Need a move up on big volume and a real break of this downtrend...and then XON will move significantly given the HUGE short interest...but right now, the shorts are still in control, even though XON has had good relative outperformance in the past couple of days.
I can't link it or yahoo will delete, but if you google "investor village" and put in XON in the message board search you can find his summary in post # 696
Bill Miller had a chance to lay out the bullish case and came across as an idiot. Worst case lose 1/2 your money, bet on CEO. Is this really his due diligence effort? I mean, what a wasted opportunity to explain what XON is really doing. Talk about a massive blunder. Nice reaction today to his thesis. I'm #$%$ at him. Herb Greenberg of CNBC did a better job. Dan Loeb did a night-and-day better job. Miller sounded uneducated. Sure hope he is more eloquent going forward.
Bill Miller pounding the table
Bill Miller, Chairman & CIO, LLM, LLC: Buy the homebuilders: likes the sector in general: mentions: KB Home (NYSE:KBH), Lennar Corporation (NYSE:LEN) & PulteGroup, Inc.(NYSE:PHM) Also really likes Intrexon Corp(NYSE:XON)
3rd idea: Also really likes XON: Interexon. Co. has licensing deals, cash coming into cover all expenses. They are working on bacteria that eats methane. Isobutanall: $11/barrel. No one has any idea if it will work. The bet is on the CEO. He owns 2/3 of XON. Worst is lose ½ your $$$. $2B company. Co. has big upside.
Shorts seem to be outmuscling Kirk, MIller and Loeb...down 50% from post-IPO high to just above IPO price.